Bispecific T-cell engagers & bispecifics

This library includes several bispecific T-cell engagers and bispecifics that have undergone regulatory review. These drugs are indicated for various cancers, including multiple myeloma, non-small cell lung cancer, small cell lung cancer, and lymphoma. The review documents provide insights into their efficacy and safety profiles, though it is important to note that different drugs were studied in different trials, so figures are not head-to-head comparisons.

For instance, Talvey demonstrated an Overall Response Rate (ORR) of 73% for its 0.4 mg/kg weekly regimen in relapsed or refractory multiple myeloma. Imdelltra showed a Median OS (tarlatamab) of 13.6 months in extensive stage small cell lung cancer, compared to 8.3 months for SoC. In relapsed or refractory diffuse large B-cell lymphoma, Tepkinly achieved an ORR for Epcoritamab 48mg (Cohort 2b Dose expansion part) of 97.6%. For relapsed or refractory multiple myeloma, Elrexfio reported an Overall Response Rate (ORR) by BICR of 75 (61.0) %.